

PRIOR AUTHORIZATION REQUEST FORM
BRAND ANTICONVULSANTS

Briviact®, Fycompa™, Vimpat®, Xcopri®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Briviact® (brivaracetam), Fycompa™ (perampanel), Vimpat® (lacosamide), Xcopri® (cenbamate)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
PARTIAL-ONSET SEIZURES			
1. Does the member have a confirmed diagnosis of partial-onset seizures?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the prescriber a neurologist or neuro-oncologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member meet the age requirement per FDA approved package labeling?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Has the member tried and failed at least 2 other anticonvulsant(s)? (Only 1 other anticonvulsant is required in patients with brain tumors)	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
TONIC-CLONIC SEIZURES			
1. Does the member have a confirmed diagnosis of tonic-clonic seizures?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the prescriber a neurologist or neuro-oncologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member meet the age requirement per FDA approved package labeling?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Has the member tried and failed at least 2 other anticonvulsant(s)? (Only 1 other anticonvulsant is required in patients with brain tumors)	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

2. Has the member’s therapy been re-evaluated within the last 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member show a continued medical need for the therapy and is tolerating treatment?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does updated documentation show improvement or stabilization in the member’s condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician’s Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM-095
 Origination Date: 02/27/2020
 Reviewed/Revised Date: 01/27/2021
 Next Review Date: 01/27/2022
 Current Effective Date: 02/01/2021

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.